Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | IDO1 | P14902 | 4/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | KIF11 | P52732 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3798782 | 0.82 | SLC6A2 (0.61) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL25342534 | 0.82 | SLC6A2 (0.61) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL1691810 | 0.82 | ESR1 (0.54) | TAAR1IDO1MAOBKIF11KMT2A | |
| SCHEMBL1720495 | 0.80 | IDO1 (0.52) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL21058264 | 0.79 | TAAR1 (0.59) | TAAR1IDO1MAOBKIF11KMT2A | |
| SCHEMBL18373466 | 0.79 | TAAR1 (0.59) | TAAR1IDO1MAOBKIF11KMT2A | |
| SCHEMBL9274712 | 0.78 | TAAR1 (0.47) | TAAR1IDO1MAOBKIF11ESR1 | |
| SCHEMBL34472339 | 0.78 | SLC6A2 (0.47) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL349725 | 0.77 | SLC6A2 (0.61) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL10262801 | 0.77 | TAAR1 (0.45) | TAAR1IDO1MAOBKIF11KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-14 | — | — | US | disclosed |
| EP-4225730-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | The Regents of the University of California (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076507-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-2647697-B1 | METHOD FOR PRODUCING HEMATOPOIETIC STEM CELLS USING PYRAZOLE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-9212348-B2 | Method for producing hematopoietic stem cells using pyrazole compounds | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| EP-2647629-B1 | PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA | NISSAN CHEMICAL IND LTD (JP) | 2015-06-17 | — | — | EP | disclosed |
| US-20140057353-A1 | METHOD FOR PRODUCING HEMATOPOIETIC STEM CELLS USING PYRAZOLE COMPOUNDS | REPROCELL INCORPORATED (JP) | 2014-02-27 | — | — | US | disclosed |
| US-8658686-B2 | Pyrazole compounds having therapeutic effect on multiple myeloma | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-02-25 | — | — | US | disclosed |
| EP-2647697-A1 | METHOD FOR PRODUCING HEMATOPOIETIC STEM CELLS USING PYRAZOLE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2013-10-09 | — | — | EP | disclosed |
| EP-2647629-A1 | PYRAZOLE COMPOUND HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA | Nissan Chemical Industries, Ltd. (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130253204-A1 | PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-26 | — | — | US | disclosed |
| WO-2012074067-A1 | PYRAZOLE COMPOUND HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA | 日産化学工業株式会社 (JP) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012074068-A1 | METHOD FOR PRODUCING HEMATOPOIETIC STEM CELLS USING PYRAZOLE COMPOUND | 日産化学工業株式会社 (JP) | 2012-06-07 | — | — | WO | disclosed |
| EP-1730126-B1 | NOVEL BENZOXAZINONE DERIVATIVES USED AS LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY ILLNESSES | BOEHRINGER INGELHEIM INT (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-8039514-B2 | Sulfonamide compounds and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100022601-A1 | SULFONAMIDE COMPOUNDS AND THE USE | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-01-28 | — | — | US | disclosed |
| US-7244728-B2 | Long acting betamimetics for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-17 | — | — | US | disclosed |
| US-20050209227-A1 | Novel long acting betamimetics for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | US | disclosed |
| EP-1577306-A1 | novel benzoxazinone derivatives as slow-acting betamimetics and use thereof in treatment of respiratory tract diseases | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209227-A1 | Novel long acting betamimetics for the treatment of respiratory diseases | ADRA1D, ADRB2, ADRA1A | SLC6A2 715/4885HTR2A 157/4885SLC6A4 1261/4885 |
| US-20130253204-A1 | PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA | MCL1, BCL6, RTN3 | SLC6A2 4249/4885HTR2A 4842/4885SLC6A4 4252/4885 |
| US-20140057353-A1 | METHOD FOR PRODUCING HEMATOPOIETIC STEM CELLS USING PYRAZOLE COMPOUNDS | HCLS1, RUNX1, HPRT1 | SLC6A2 2728/4885HTR2A 4429/4885SLC6A4 1609/4885 |
| US-20100022601-A1 | SULFONAMIDE COMPOUNDS AND THE USE | PTH1R, CASR, SOST | SLC6A2 3750/4885HTR2A 3685/4885SLC6A4 2788/4885 |
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | PRMT8, SIRT1, PRMT3 | SLC6A2 3591/4885HTR2A 2772/4885SLC6A4 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.